Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer

BACKGROUND: The effectiveness of atezolizumab plus nab-paclitaxel for advanced triple-negative breast cancer (TNBC) has been demonstrated. We aimed to evaluate its cost-effectiveness on advanced TNBC from the US payer perspective. METHODS: A Markov model was adopted to project the disease course of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Bin, Ma, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222249/
https://www.ncbi.nlm.nih.gov/pubmed/32426048
http://dx.doi.org/10.1177/1758835920916000

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222249/
https://www.ncbi.nlm.nih.gov/pubmed/32426048
http://dx.doi.org/10.1177/1758835920916000

Ejemplares similares